BRCA2 sirna

BRCA2 siRNA (Human)

Cat. Num. AAA8206072

• Gene Names: BRCA2; FAD; FACD; FAD1; GLM3; BRCC2; FANCD; PNCA2; FANCD1; XRCC11; BROVCA2
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: BRCA2; BRCA2 siRNA (Human); FACD; FANCD1; Breast cancer type 2 susceptibility protein; Fanconi anemia group D1 protein; BRCA2 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: BRCA2 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 3,418

• Applicable Applications for BRCA2 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human BRCA2 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for BRCA2 sirna

siRNA to inhibit BRCA2 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 119395734
• NCBI GeneID: 675
• NCBI Accession #: NP_000050.2
• NCBI GenBank Nucleotide #: NM_000059.3
• UniProt Accession #: P51587; O00183; O15008; Q13879; Q5TBJ7
• Molecular Weight: 384,225 Da
• NCBI Official Full Name: breast cancer type 2 susceptibility protein
• NCBI Official Synonym Full Names: breast cancer 2, early onset
• NCBI Official Symbol: BRCA2
• NCBI Official Synonym Symbols: FAD; FACD; FAD1; GLM3; BRCC2; FANCD; PNCA2; FANCD1; XRCC11; BROVCA2
• NCBI Protein Information: breast cancer type 2 susceptibility protein
• UniProt Protein Name: Breast cancer type 2 susceptibility protein
• Protein Family: BRCA2 and CDKN1A-interacting protein
• UniProt Gene Name: BRCA2
• UniProt Synonym Gene Names: FACD; FANCD1
• UniProt Entry Name: BRCA2_HUMAN

NCBI Description

Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele. [provided by RefSeq, Dec 2008]

Uniprot Description

BRCA2: involved in double-strand break repair and/or homologous recombination. May participate in S phase checkpoint activation. Interacts with RAD51 and DSS1. Interacts with ubiquitinated FANCD2. Interacts with PALB2, enables the recombinational repair and checkpoint functions. Interacts with WDR16. Defects in BRCA2 are a cause of genetic susceptibility to breast cancer and may underlie susceptibility to uveal melanoma.

Protein type: Nuclear receptor co-regulator; Tumor suppressor; DNA repair, damage

Chromosomal Location of Human Ortholog: 13q12.3

Cellular Component: nucleoplasm; centrosome; protein complex; cytoplasm; BRCA2-MAGE-D1 complex; nucleus; secretory granule

Molecular Function: protein binding; gamma-tubulin binding; H4 histone acetyltransferase activity; histone acetyltransferase activity; protease binding; H3 histone acetyltransferase activity; single-stranded DNA binding

Biological Process: positive regulation of transcription, DNA-dependent; cell aging; cytokinesis; DNA repair; positive regulation of mitotic cell cycle; oocyte maturation; regulation of cytokinesis; inner cell mass cell proliferation; negative regulation of mammary gland epithelial cell proliferation; response to UV-C; double-strand break repair via homologous recombination; DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; male meiosis I; nucleotide-excision repair; double-strand break repair; response to gamma radiation; replication fork protection; hemopoiesis; spermatogenesis; brain development; centrosome duplication; DNA damage response, signal transduction by p53 class mediator resulting in induction of apoptosis; female gonad development; response to X-ray

Disease: Pancreatic Cancer, Susceptibility To, 2; Breast-ovarian Cancer, Familial, Susceptibility To, 2; Breast Cancer; Prostate Cancer; Medulloblastoma; Glioma Susceptibility 3; Tracheoesophageal Fistula With Or Without Esophageal Atresia; Fanconi Anemia, Complementation Group D1; Wilms Tumor 1